Researchers at Calibr-Skaggs are developing CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining.
